Antiestrogen resistance in ER positive breast cancer cells

Soonmyoung Paik, Dan Paul Hartmann, Robert B. Dickson, Marc E Lippman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30% of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.

Original languageEnglish
Pages (from-to)301-307
Number of pages7
JournalBreast Cancer Research and Treatment
Volume31
Issue number2-3
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Breast Neoplasms
Phenotype
MCF-7 Cells
Metabolic Networks and Pathways
Organism Cloning
Signal Transduction
Cell Line
Pharmaceutical Preparations
Population
Neoplasms

Keywords

  • antiestrogen resistance
  • breast cancer
  • estrogen receptor
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Paik, S., Hartmann, D. P., Dickson, R. B., & Lippman, M. E. (1994). Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Research and Treatment, 31(2-3), 301-307. https://doi.org/10.1007/BF00666162

Antiestrogen resistance in ER positive breast cancer cells. / Paik, Soonmyoung; Hartmann, Dan Paul; Dickson, Robert B.; Lippman, Marc E.

In: Breast Cancer Research and Treatment, Vol. 31, No. 2-3, 01.01.1994, p. 301-307.

Research output: Contribution to journalArticle

Paik, S, Hartmann, DP, Dickson, RB & Lippman, ME 1994, 'Antiestrogen resistance in ER positive breast cancer cells', Breast Cancer Research and Treatment, vol. 31, no. 2-3, pp. 301-307. https://doi.org/10.1007/BF00666162
Paik, Soonmyoung ; Hartmann, Dan Paul ; Dickson, Robert B. ; Lippman, Marc E. / Antiestrogen resistance in ER positive breast cancer cells. In: Breast Cancer Research and Treatment. 1994 ; Vol. 31, No. 2-3. pp. 301-307.
@article{4078fd2f691243bc857c8ef523424ae7,
title = "Antiestrogen resistance in ER positive breast cancer cells",
abstract = "Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30{\%} of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.",
keywords = "antiestrogen resistance, breast cancer, estrogen receptor, tamoxifen",
author = "Soonmyoung Paik and Hartmann, {Dan Paul} and Dickson, {Robert B.} and Lippman, {Marc E}",
year = "1994",
month = "1",
day = "1",
doi = "10.1007/BF00666162",
language = "English",
volume = "31",
pages = "301--307",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2-3",

}

TY - JOUR

T1 - Antiestrogen resistance in ER positive breast cancer cells

AU - Paik, Soonmyoung

AU - Hartmann, Dan Paul

AU - Dickson, Robert B.

AU - Lippman, Marc E

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30% of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.

AB - Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30% of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.

KW - antiestrogen resistance

KW - breast cancer

KW - estrogen receptor

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0028138770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028138770&partnerID=8YFLogxK

U2 - 10.1007/BF00666162

DO - 10.1007/BF00666162

M3 - Article

VL - 31

SP - 301

EP - 307

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2-3

ER -